Magnetic-resonance imaging in diagnostics of esophageal cancer (literature review)

Carcinoma of the esophagus continues to be a malignant disease with a poor prognosis; the overall five-year survival rate ranges from 15 to 20%. Esophageal cancer is the eighth most common and the sixth most common cause of death among oncological diseases. The main task of esophageal cancer diagnostics is to assess the extent of the pathological process in order to determine the most optimal type of medical care. Currently, endoscopic ultrasonography (EUS) is considered to be the method of choice in determining the T-stage of the primary tumor. Moreover, several studies have shown the better results in N staging using EUS with TAB. At the same time, MRI of the esophagus is considered to be a technically challenging procedure because of difficulties in visualizing due to the motion artifacts. The motor and flow artifacts arising from the heartbeats and pulsations of the aorta and pulmonary vessels significantly reduce the quality of images. Nevertheless, the emergence in the last decade of some technical innovations can significantly reduce the impact of motion artifacts on image quality. For example, the effect of respiratory movements can be leveled using the proposed r-VIBE (radial VIBE) sequence, in which scanning and data collection occurs on the patient’s free breathing. However, in order to obtain high-quality images of the esophagus,(and make accurate staging of esophageal cancer, respectively) it is necessary to use different sequences; the scanning protocol must include T2-WI in several planes using high resolution sequences, DWI, and T1-WI with dynamic contrast enhancement. Application of new data collection technologies allowed to study esophagus on the expert level and to assess the local extent of the process accurately. Moreover, significant progress has been reached in assessing of N-stage in esophageal cancer with MRI in recent years. Unfortunately, a unified sequence protocol has not been developed yet and that makes it difficult to perform a statistical proper meta-analysis.
Creating conditions for esophageal cancer treatment indicates development of response predictors to the neoadjuvant chemoradiotherapy (nCRT), which would reliably determine the tumor response rate and likelihood before starting treatment, as well as creating reliable response criteria in the early periods after nCRT based on objective medical imaging data.
Another task is creatin of an artifact-decreasing sequence protocol, which would allow to determine the
extent of the lesion accurately. In addition, it is necessary to study the possibilities of MRI in the tumor staging, in comparison with the results obtained with EUS, CT, PET-CT in the form of a prospective study with a large sample of patients. 

1. Wong R., Walker-Dilks C., Raifu A. Evidence-based guideline recommendations on the use of positron emission tomography imaging in oesophageal cancer. Clin. Oncol. 2012; n24: 86–104. https://doi.org/10.1016/j.clon.2011.09.006.

2. DeSantis C.E., Lin C.C., Mariotto A.B., Siegel R.L., Stein K.D., Kramer J.L., Alteri R., Robbins A.S., Jemal A. Cancer treatment and survivorship statistics. CA. Cancer. J. Clin. 2014; 64: 252–257. https://doi.org/10.3322/caac.21235.

3. Wallace M.B., Nietert P.J., Earle C., Krasna MJ, Hawes RH, Hoffman BJ, Reed CE.. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann. Thorac. Surg. 2002; 74: 1026–1032.

4. Rustgi A.K., El-Serag H.B. Esophageal carcinoma. N. Engl. J. Med. 2014; 371: 2499–2509. https://doi.org/10.1056/NEJMra1314530.

5. van Westreenen H.L., Heeren P.A., van Dullemen H.M., van der Jagt E.J., Jager P.L., Groen H., Plukker J.T. Positron emission tomography with F-18-fluoro deoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgicalexplorations. J. Gastrointest. Surg. 2005; 9 (1): 54–61.

6. Arnold M., Soerjomataram I., Ferlay .J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015; 64: 381–387. https://doi.org/10.1136/gutjnl-2014-308124.

7. Block K,, Chandarana H,, Milla S,, Bruno M,, Mulholland T., Fatterpekar G., Hagiwara M., Grimm G., Geppert C., Kiefer B., Sodickson D.K. Towards routine clinical use of radial stack-of-stars 3D gradient-echo sequencesfor reducing motion sensitivity. J. Korean Soc. Magn. Reson. Med. 2014; 18: 87–106. https://doi.org/10.13104/jksmrm.2014.18.2.87.

8. Lepage C., Drouillard A., Jouve J., Faivre J. Epidemiology and risk factors for Oesophageal adenocarcinoma. Dig. Liver. Dis. 2013; 45: 625–629. https://doi.org/10.1016/j.dld.2012.12.020.

9. Azevedo R.M., de Campos R.O., Ramalho M. Herédia V., Dale B.M., Semelka R.C. Freebreathing 3D T1-weighted gradient-echo sequence with radial data sampling in abdominal MRI: preliminary observations. Am. J. Roentgenol. 2001; 197: 650–657.

10. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Globocan 2012 v1.1, Cancer Incidence and mortality worldwide: IARC CancerBase No. 11.

11. Chandarana H., Block K.T., Winfeld M.J., Lala S.V., Mazori D., Giuffrida E., Babb J.S., Milla S.S. Freebreathing contrast-enhanced T1-weighted gradient-echo imaging with radial k-space sampling for paediatric abdominopelvic MRI. 2014; Eur. Radiol. 24: 320–326. https://doi.org/10.1007/s00330-013-3026-4.

12. Hongo M., Nagasaki Y., Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J. Gastroenterol. Hepatol. 2009; 24: 729–735. https://doi.org/10.1111/j.1440-1746.2009.05824.x.

13. Fujinaga Y., Ohya A., Tokoro H., Yamada A., Ueda K., Ueda H., Kitou Y., Adachi Y., Shiobara A., Tamaru N., Nickel M.D., Maruyama K., Kadoya M. Radial volumetric imagingbreath-hold examination (VIBE) with k-space weighted imagecontrast (KWIC) for dynamic gadoxetic acid (Gd-EOBDTPA)-enhanced MRI of the liver: advantages over CartesianVIBE in the arterial phase. Eur. Radiol. 2014; 24: 1290–1299. https://doi.org/10.1007/s00330-014-3122-0.

14. Kaprin A.D., Starinskij V.V., Petrov G.V. Malignant neoplasms in Russia in 2016 (morbidity and mortality). M.: MNIOI im. P.A. Gercena – filial FGBU “NMIRC” Minzdrava Rossii, 2017. 236 p. (In Russian)

15. Lever F.M., Lips I.M., Crijns S.P., Reerink O., van Lier A.L., Moerland M.A., van Vulpen M., Meijer G.J. Quantification of esophageal tumormotion on cine-magnetic resonance imaging. Int. J. Radiat. Onco.l Biol. Phys. 2014; 88: 419–424. https://doi.org/10.1016/j.ijrobp.2013.10.036.

16. Quint L.E., Bogot N.R. Staging esophageal cancer. Cancer Imaging. 2008; 8 Spec No A: S33–S42. https://doi.org/10.1102/1470-7330.2008.9007.

17. Riddell A.M., Allum W.H., Thompson J.N., Wotherspoon A.C., Richardson C., Brown G. The appearances of oesophageal carcinoma demonstrated on highresolution, T2-weighted MRI, with histopathological correlation. Eur. Radiol. 2007; 17: 391–399.

18. Kelly S., Harris K.M., Berry E., Hutton J., Roderick P., Cullingworth J., Gathercole L., Smith M.A. A systematic review of the staging performance of endoscopic ultrasound in gastrooesophageal carcinoma. Gut. 2001; 49: 534–539.

19. Yamada I., Miyasaka N., Hikishima K., Tokairin Y., Kawano T., Ito E., Kobayashi D., Eishi Y., Okano H. Ultrahigh-resolution MR imaging of esophageal carcinoma at ultra-high field strength (7.0 T) ex vivo: correlation with histopathologic finding. Magn. Reson. Imaging. 2015; 33 (4): 413–419. https://doi.org/10.1016/j.mri.2014.11.005.

20. Wakelin S.J., Deans C., Crofts T.J., Allan P.L., Plevris J.N., Paterson-Brown S. A comparison of computerised tomography, laparoscopic ultrasound and endoscopic ultrasound in the preoperative staging of oesophagogastric carcinoma. Eur. J. Radiol. 2002; 41: 161–167.

21. Riddell A.M., Hillier J., Brown G., King D.M., Wotherspoon A.C., Thompson J.N., Cunningham D., Allum W.H.. Potential of Surface-Coil MRI for Staging of Esophageal Cancer. Am. J. Roentgenol. 2006; 187 (5): 1280–1287.

22. Rice T.W. Clinical staging of esophageal carcinoma. CT, EUS, and PET. Chest Surg. Clin. N. Am. 2000; 10: 471–485.

23. Panfilenko A.F., Yakovlev S.A., Pozdnyakov A.V., Tyutin L.A., Shcherbuk A.Yu. MRI with dynamic contrast enhancement in brain tumors. Problems of Oncology. 2013; 59 (1): 83–88. (In Russian)

24. Wayman J., Chakraverty S., Griffin S.M., Doyle G.J., Keir M.J., SimpsonW. Evaluation of local invasion by oesophageal carcinoma–aprospective study of prone computed tomography scanning. Postgrad. Med. J. 2001; 77: 181–184.

25. Chang E.Y., Li X., Jerosch-Herold M., Priest R.A., Enestvedt C.K., Xu J., Springer C.S. jr., Jobe B.A. The evaluation of esophageal adenocarcinoma usingdynamic contrast-enhanced magnetic resonance imaging. J. Gastrointest. Surg. 2008; 12: 166–175.

26. Diederich S. Staging of oesophageal cancer. Cancer Imaging. 2007; 7 Spec No A: S63–S66.

27. Lei J., Tian Y., Zhu S.-C., Han Q., Wei Y., Yang S.,. Shi D.-P 2015 Preliminary study of IVIM-DWI and DCE-MRI in early diagnosis of esophageal cancer. Eur. Rev. Med. Pharmaco. l Sci. 2015; 19 (18): 3345–3350.

28. Eloubeidi M.A., Wallace M.B., Reed C.E. Hadzijahic N., Lewin D.N., Van Velse A., Leveen M.B., Etemad B., Matsuda K., Patel R.S., Hawes R.H., Hoffman B.J. The utility of EUS and EUS-guided fine needle aspiration in detecting celiac lymph node metastasis in patients with esophageal cancer: a single-center experience. Gastrointest. Endosc. 2001; 54: 714–719.

29. Koh D.M., Collins D.J. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am. J. Roentgenol. 2007; 188: 1622–1635. https://doi.org/10.2214/AJR.06.1403.

30. Vazquez-Sequeiros E., Norton I.D., Clain J.E. Wang K.K., Affi A., Allen M., Deschamps C., Miller D., Salomao D., Wiersema M.J. Impact of EUS-guided fine-needle aspiration on lymph node staging in patients with esophageal carcinoma. Gastrointest Endosc. 2001; 53: 751–757.

31. Takashima S., Takeuchi N., Shiozaki H., Kobayashi K., Morimoto S., Ikezoe J., Tomiyama N., Harada K., Shogen K., Kozuka T. Carcinoma of the esophagus: CT vs MR imaging in determining resectability. Am. J. Roentgenol. 1991; 156: 297–302.

32. Rasanen J.V., Sihvo E.I., Knuuti M.J., Minn H.R., Luostarinen M.E., Laippala P., Viljanen T., Salo J.A. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann. Surg. Oncol. 2003; 10: 954–960.

33. Ajani J.A., Barthel J.S., Bentrem D.J. Besh S., Chao J., Das P., Denlinger C., Fanta P., Fuchs C.S., Gerdes H., Glasgow R.E., Hayman J.A., Hochwald S., Hofstetter W.L., Ilson D.H., Jaroszewski D., Jasperson K., Keswani R.N., Kleinberg L.R., Korn W.M., Leong S., Lockhart A.C., Mulcahy M.F., Orringer M.B., Posey J.A., Poultsides G.A., Sasson A.R., Scott W.J., Strong V.E., Varghese T.K. Jr., Washington M.K., Willett C.G., Wright C.D., Zelman D., McMillian N., Sundar H., National comprehensive cancer network. Esophageal and esophagogastric junction cancers. J. Natl. Compr. Cancer. Netw. 2011; 9: 830–887.

34. Luketich J.D., Schauer P., Landreneau R., Nguyen N., Urso K., Ferson P., Keenan R., Kim R. Minimally invasive surgical staging is superior to endoscopic ultrasound in detecting lymph node metastases in esophageal cancer. J. Thorac. Cardiovasc. Surg. 1997; 114: 817–821, discussion 821–823.

35. Nakashima A., Nakashima K., Seto H., Kakishita M., Sakamoto T., Yamada A., Fujimaki M. Thoracic esophageal carcinoma:evaluation in the sagittal section with magnetic resonance imaging. Abdom. Imaging. 1997; 22: 20–23.

36. Allum W.H., Blazeby J.M., Griffin S.M., Cunningham D., Jankowski J.A., Wong R. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011; 60: 1449–1472. https://doi.org/10.1136/gut.2010.228254.

37. Wu L.F., Wang B.Z., Feng J.L., Cheng W.R., Liu G.R., Xu X.H., Zheng Z.C. Preoperative TN staging of esophageal cancer: comparison of miniprobe ultrasonography, spiral CT and MRI. Wld J. Gastroenterol. 2003; 9: 219–224.

38. Wong R., Walker-Dilks C., Raifu A. Evidence-based guideline recommendations on the use of positron emission tomography imaging in oesophageal cancer. Clin. Oncol. 2012; n24: 86–104. https://doi.org/10.1016/j.clon.2011.09.006.

39. Yamada I., Murata Y., Izumi Y., Kawano T., Endo M., Kuroiwa T., Shibuya H. Staging of esophageal carcinoma in vitro with 4.7-T MR imaging. Radiology. 1997; 204: 521–526.

40. Wallace M.B., Nietert P.J., Earle C., Krasna MJ, Hawes RH, Hoffman BJ, Reed CE.. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann. Thorac. Surg. 2002; 74: 1026–1032.

41. Yamada I., Izumi Y., Kawano T., Yoshino N., Tetsumura A., Kumagai J., Shibuya H. Esophageal carcinoma: evaluation with high-resolution three-dimensional constructive interference in steady state MR imaging in vitro. J. Magn. Reson. Imaging. 2006; 24: 1326–1332. https://doi.org/10.1002/jmri.20741.

42. van Westreenen H.L., Heeren P.A., van Dullemen H.M., van der Jagt E.J., Jager P.L., Groen H., Plukker J.T. Positron emission tomography with F-18-fluoro deoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgicalexplorations. J. Gastrointest. Surg. 2005; 9 (1): 54–61.

43. Sakurada A., Takahara T., Kwee T.C., Yamashita T., Nasu S., Horie T., Van Cauteren M., Imai Y. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Eur. Radiol. 2009; 19: 1461–1469. https://doi.org/10.1007/s00330-008-1291-4.

44. Block K,, Chandarana H,, Milla S,, Bruno M,, Mulholland T., Fatterpekar G., Hagiwara M., Grimm G., Geppert C., Kiefer B., Sodickson D.K. Towards routine clinical use of radial stack-of-stars 3D gradient-echo sequencesfor reducing motion sensitivity. J. Korean Soc. Magn. Reson. Med. 2014; 18: 87–106. https://doi.org/10.13104/jksmrm.2014.18.2.87.

45. Yamada I., Hikishima K., Miyasaka N., Kawano T., Tokairin Y., Ito E., Kobayashi D., Eishi Y., Okano H. Esophageal carcinoma: Ex vivo evaluation with diffusion tensor MR imaging and tractography at 7 T. Radiology. 2014; 272: 164 173. https://doi.org/10.1148/radiol.14132170.

46. Azevedo R.M., de Campos R.O., Ramalho M. Herédia V., Dale B.M., Semelka R.C. Freebreathing 3D T1-weighted gradient-echo sequence with radial data sampling in abdominal MRI: preliminary observations. Am. J. Roentgenol. 2001; 197: 650–657.

47. Petrillo R., Balzarini L., Bidoli P., Ceglia E., D'Ippolito G., Tess J.D., Musumeci R. Esophageal squamous cell carcinoma:MRI evaluation of mediastinum. Gastrointest. Radiol. 1990; 15: 275–278.

48. Chandarana H., Block K.T., Winfeld M.J., Lala S.V., Mazori D., Giuffrida E., Babb J.S., Milla S.S. Freebreathing contrast-enhanced T1-weighted gradient-echo imaging with radial k-space sampling for paediatric abdominopelvic MRI. 2014; Eur. Radiol. 24: 320–326. https://doi.org/10.1007/s00330-013-3026-4.

49. Takashima S., Takeuchi N., Shiozaki H., Kobayashi K., Morimoto S., Ikezoe J., Tomiyama N., Harada K., Shogen K., Kozuka T. Carcinoma of the esophagus: CT vs MR imaging in determining resectability. Am. J. Roentgenol. 1991; 156: 297–302.

50. Fujinaga Y., Ohya A., Tokoro H., Yamada A., Ueda K., Ueda H., Kitou Y., Adachi Y., Shiobara A., Tamaru N., Nickel M.D., Maruyama K., Kadoya M. Radial volumetric imagingbreath-hold examination (VIBE) with k-space weighted imagecontrast (KWIC) for dynamic gadoxetic acid (Gd-EOBDTPA)-enhanced MRI of the liver: advantages over CartesianVIBE in the arterial phase. Eur. Radiol. 2014; 24: 1290–1299. https://doi.org/10.1007/s00330-014-3122-0.

51. Qu J., Zhang H., Wang Z., Zhang F., Liu H., Ding Z., Li Y., Ma J., Zhang Z., Zhang S., Dong Y., Jiang L., Zhang W., Grimm R., Kiefer B., Kamel I.R., Qin J., Li H. 2017 Comparison between free-breathing radial VIBE on 3-T MRI and endoscopic ultrasound for preoperative T staging of resectable oesophageal cancer, with histopathological correlation. Eur. Radiol. 2018; 28 (2): 780–787. https://doi.org/10.1007/s00330-017-4963-0.

52. Lever F.M., Lips I.M., Crijns S.P., Reerink O., van Lier A.L., Moerland M.A., van Vulpen M., Meijer G.J. Quantification of esophageal tumormotion on cine-magnetic resonance imaging. Int. J. Radiat. Onco.l Biol. Phys. 2014; 88: 419–424. https://doi.org/10.1016/j.ijrobp.2013.10.036.

53. Lerut T.E., de Leyn P., Coosemans W., Van Raemdonck D., Cuypers P., Van Cleynenbreughel B. Advanced esophageal carcinoma. Wld J. Surg. 1994; 18: 379–387.

54. Riddell A.M., Allum W.H., Thompson J.N., Wotherspoon A.C., Richardson C., Brown G. The appearances of oesophageal carcinoma demonstrated on highresolution, T2-weighted MRI, with histopathological correlation. Eur. Radiol. 2007; 17: 391–399.

55. Waterman T.A., Hagen J.A., Peters J.H., DeMeester S.R., Taylor C.R., Demeester T.R. The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma. Ann. Thorac. Surg. 2004; 78: 1161–1169.

56. Yamada I., Miyasaka N., Hikishima K., Tokairin Y., Kawano T., Ito E., Kobayashi D., Eishi Y., Okano H. Ultrahigh-resolution MR imaging of esophageal carcinoma at ultra-high field strength (7.0 T) ex vivo: correlation with histopathologic finding. Magn. Reson. Imaging. 2015; 33 (4): 413–419. https://doi.org/10.1016/j.mri.2014.11.005.

57. Kayani B., Zacharakis E., Ahmed K., Hanna G.B. Lymph node metastases and prognosis in oesophageal carcinoma – a systematic review. Eur. J. Surg. Oncol. 2011; 37: 747–753. https://doi.org/10.1016/j.ejso.2011.06.018.

58. Riddell A.M., Hillier J., Brown G., King D.M., Wotherspoon A.C., Thompson J.N., Cunningham D., Allum W.H.. Potential of Surface-Coil MRI for Staging of Esophageal Cancer. Am. J. Roentgenol. 2006; 187 (5): 1280–1287.

59. Quint L.E., Glazer G.M., Orringer M.B. Esophageal imaging by MR and CT: study of normal anatomy and neoplasms. Radiology. 1985; 156: 727–731.

60. Panfilenko A.F., Yakovlev S.A., Pozdnyakov A.V., Tyutin L.A., Shcherbuk A.Yu. MRI with dynamic contrast enhancement in brain tumors. Problems of Oncology. 2013; 59 (1): 83–88. (In Russian)

61. Petrillo R., Balzarini L., Bidoli P. Ceglia E, D'Ippolito G, Tess JD, Musumeci R. Esophageal squamous cell carcinoma: MRI evaluation of mediastinum. Gastrointest. Radiol. 1990; 15: 275–278.

62. Chang E.Y., Li X., Jerosch-Herold M., Priest R.A., Enestvedt C.K., Xu J., Springer C.S. jr., Jobe B.A. The evaluation of esophageal adenocarcinoma usingdynamic contrast-enhanced magnetic resonance imaging. J. Gastrointest. Surg. 2008; 12: 166–175.

63. Nishimura H., Tanigawa N., Hiramatsu M., Tatsumi Y., Matsuki M., Narabayashi I. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superpara magnetic iron oxide. J. Am. Coll. Surg. 2006; 202: 604–611.

64. Lei J., Tian Y., Zhu S.-C., Han Q., Wei Y., Yang S.,. Shi D.-P 2015 Preliminary study of IVIM-DWI and DCE-MRI in early diagnosis of esophageal cancer. Eur. Rev. Med. Pharmaco. l Sci. 2015; 19 (18): 3345–3350.

65. Mizowaki T., Nishimura Y., Shimada Y., Nakano Y., Imamura M., Konishi J., Hiraoka M. Optimal size criteria of malignant lymph nodes in the treatment planning of radiotherapy for esophageal cancer: evaluation by computed tomography and magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 1996; 36: 1091–1098.

66. Koh D.M., Collins D.J. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am. J. Roentgenol. 2007; 188: 1622–1635. https://doi.org/10.2214/AJR.06.1403.

67. Alper F., Turkyilmaz A., Kurtcan S. Aydin Y., Onbas O., Acemoglu H., Eroglu A. Effectiveness of the STIR turbo spin-echo sequence MR imaging in evaluation oflymphadenopathy in esophageal cancer. J. Radiol. 2011; 80: 625–628.

68. Takashima S., Takeuchi N., Shiozaki H., Kobayashi K., Morimoto S., Ikezoe J., Tomiyama N., Harada K., Shogen K., Kozuka T. Carcinoma of the esophagus: CT vs MR imaging in determining resectability. Am. J. Roentgenol. 1991; 156: 297–302.

69. van Hagen P., Hulshof M.C.C.M., van Lanschot J.J., Steyerberg E.W., van Berge Henegouwen M.I., Wijnhoven B.P., Richel D.J., Nieuwenhuijzen G.A., Hospers G.A., Bonenkamp J.J., Cuesta M.A., Blaisse R.J., Busch O.R., ten Kate F.J., Creemers G.J., Punt C.J., Plukker J.T., Verheul H.M., Spillenaar Bilgen E.J., van Dekken H., van der Sangen M.J., Rozema T., Biermann K., Beukema J.C., Piet A.H., van Rij C.M., Reinders J.G., Tilanus H.W., van der Gaast A. CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 2012; 22: 2074–2084. https://doi.org/10.1056/NEJMoa1112088.

70. Ajani J.A., Barthel J.S., Bentrem D.J. Besh S., Chao J., Das P., Denlinger C., Fanta P., Fuchs C.S., Gerdes H., Glasgow R.E., Hayman J.A., Hochwald S., Hofstetter W.L., Ilson D.H., Jaroszewski D., Jasperson K., Keswani R.N., Kleinberg L.R., Korn W.M., Leong S., Lockhart A.C., Mulcahy M.F., Orringer M.B., Posey J.A., Poultsides G.A., Sasson A.R., Scott W.J., Strong V.E., Varghese T.K. Jr., Washington M.K., Willett C.G., Wright C.D., Zelman D., McMillian N., Sundar H., National comprehensive cancer network. Esophageal and esophagogastric junction cancers. J. Natl. Compr. Cancer. Netw. 2011; 9: 830–887.

71. Dvoreckij S.Ju. Modern esophageal cancer treatment strategy. Vestnik khirurgii im. I.I. Grekova. 2016. 4: 102–107. https://doi.org/10.24884/0042-4625-2016-175-4-102-107. (In Russian)

72. Nakashima A., Nakashima K., Seto H., Kakishita M., Sakamoto T., Yamada A., Fujimaki M. Thoracic esophageal carcinoma:evaluation in the sagittal section with magnetic resonance imaging. Abdom. Imaging. 1997; 22: 20–23.

73. Mandard A.M., Dalibard F., Mandard J.C., Marnay J., Henry-Amar M., Petiot J.H., Roussel A., Jacob J.H., Segol P., Samama G., Ollivier J.M., Bonvalot S., Gignoux M. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994. 11: 2680–2686.

74. Wu L.F., Wang B.Z., Feng J.L., Cheng W.R., Liu G.R., Xu X.H., Zheng Z.C. Preoperative TN staging of esophageal cancer: comparison of miniprobe ultrasonography, spiral CT and MRI. Wld J. Gastroenterol. 2003; 9: 219–224.

75. Sendler A. Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res. 2010; 182: 167–177. https://doi.org/10.1007/978-3-540-70579-6_14

76. Yamada I., Murata Y., Izumi Y., Kawano T., Endo M., Kuroiwa T., Shibuya H. Staging of esophageal carcinoma in vitro with 4.7-T MR imaging. Radiology. 1997; 204: 521–526.

77. Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., Scarffe J.H., Lofts F.J., Falk S.J., Iveson T.J., Smith D.B., Langley R.E., Verma M., Weeden S., Chua Y.J., MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006; 355: 11–20.

78. Yamada I., Izumi Y., Kawano T., Yoshino N., Tetsumura A., Kumagai J., Shibuya H. Esophageal carcinoma: evaluation with high-resolution three-dimensional constructive interference in steady state MR imaging in vitro. J. Magn. Reson. Imaging. 2006; 24: 1326–1332. https://doi.org/10.1002/jmri.20741.

79. Schandl A., Lagergren J., Johar A., Lagergren P. Healthrelated quality of life 10 years after oesophageal cancer surgery. Eur. J. Cancer. 2016; 69: 43–50. https://doi.org/10.1016/j.ejca.2016.09.032.

80. Sakurada A., Takahara T., Kwee T.C., Yamashita T., Nasu S., Horie T., Van Cauteren M., Imai Y. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Eur. Radiol. 2009; 19: 1461–1469. https://doi.org/10.1007/s00330-008-1291-4.

81. Hayashida Y., Yakushiji T., Awai K., Katahira K., Nakayama Y., Shimomura O., Kitajima M., Hirai T., Yamashita Y., Mizuta H. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur. Radiol. 2006; 16: 2637–2643.

82. Yamada I., Hikishima K., Miyasaka N., Kawano T., Tokairin Y., Ito E., Kobayashi D., Eishi Y., Okano H. Esophageal carcinoma: Ex vivo evaluation with diffusion tensor MR imaging and tractography at 7 T. Radiology. 2014; 272: 164 173. https://doi.org/10.1148/radiol.14132170.

83. Galban C.J., Mukherji S.K., Chenevert T.L., Meyer C.R., Hamstra D.A., Bland P.H., Johnson T.D., Moffat B.A., Rehemtulla A., Eisbruch A., Ross B.D. A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl. Oncol. 2009; 2: 184–190.

84. Petrillo R., Balzarini L., Bidoli P., Ceglia E., D'Ippolito G., Tess J.D., Musumeci R. Esophageal squamous cell carcinoma:MRI evaluation of mediastinum. Gastrointest. Radiol. 1990; 15: 275–278.

85. Sun N.N., Liu C., Ge X.L. Dynamic contrast-enhanced MRI for advanced esophageal cancer response assessment after concurrent chemoradiotherapy. Diagn. Interv. Radiol. 2018; 24: 195–202. https://doi.org/10.5152/dir.2018.17369.

86. Takashima S., Takeuchi N., Shiozaki H., Kobayashi K., Morimoto S., Ikezoe J., Tomiyama N., Harada K., Shogen K., Kozuka T. Carcinoma of the esophagus: CT vs MR imaging in determining resectability. Am. J. Roentgenol. 1991; 156: 297–302.

87. Patterson D.M., Padhani A.R., Collins D.J. Technology insight: water diffusion MRI – a potential new biomarker of response to cancer therapy. Nat. Clin. Pract. Oncol. 2008; 4: 220–233. https://doi.org/10.1038/ncponc1073.

88. Qu J., Zhang H., Wang Z., Zhang F., Liu H., Ding Z., Li Y., Ma J., Zhang Z., Zhang S., Dong Y., Jiang L., Zhang W., Grimm R., Kiefer B., Kamel I.R., Qin J., Li H. 2017 Comparison between free-breathing radial VIBE on 3-T MRI and endoscopic ultrasound for preoperative T staging of resectable oesophageal cancer, with histopathological correlation. Eur. Radiol. 2018; 28 (2): 780–787. https://doi.org/10.1007/s00330-017-4963-0.

89. Aoyagi T., Shuto K., Okazumi S., Shimada H., Kazama T., Matsubara H. Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer. Dig. Surg. 2011; 4: 252–257. https://doi.org/10.1159/000328770.

90. Lerut T.E., de Leyn P., Coosemans W., Van Raemdonck D., Cuypers P., Van Cleynenbreughel B. Advanced esophageal carcinoma. Wld J. Surg. 1994; 18: 379–387.

91. van Rossum P.S., van Lier A.L., van Vulpen M., Reerink O., Lagendijk J.J., Lin S.H., van Hillegersberg R., Ruurda J.P., Meijer G.J., Lips I.M. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer. Radiother. Oncol. 2015; 2: 163–170. https://doi.org/10.1016/j.radonc.2015.04.027.

92. Waterman T.A., Hagen J.A., Peters J.H., DeMeester S.R., Taylor C.R., Demeester T.R. The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma. Ann. Thorac. Surg. 2004; 78: 1161–1169.

93. De Cobelli F., Giganti F., Orsenigo E., Cellina M., Esposito A., Agostini G., Albarello L., Mazza E., Ambrosi A., Socci C., Staudacher C., Del Maschio A. Apparent diffusion coefficient modifications in assessing gastrooesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology. Eur. Radiol. 2013; 8: 2165–2174. https://doi.org/10.1007/s00330-013-2807-0.

94. Kayani B., Zacharakis E., Ahmed K., Hanna G.B. Lymph node metastases and prognosis in oesophageal carcinoma – a systematic review. Eur. J. Surg. Oncol. 2011; 37: 747–753. https://doi.org/10.1016/j.ejso.2011.06.018.

95. Wang L., Liu L., Han C., Liu S., Tian H., Li Z., Ren X., Shi G., Wang Q., Wang G. The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy. Radiother. Oncol. 2016; 2: 246–251. https://doi.org/10.1016/j.radonc.2016.10.021.

96. Quint L.E., Glazer G.M., Orringer M.B. Esophageal imaging by MR and CT: study of normal anatomy and neoplasms. Radiology. 1985; 156: 727–731.

97. Patel U.B., Taylor F., Blomqvist L., George C., Evans H., Tekkis P., Quirke P., Sebag-Montefiore D., Moran B., Heald R., Guthrie A., Bees N., Swift I., Pennert K., Brown G. Magnetic Resonance Imaging-Detected Tumor Response for Locally Advanced Rectal Cancer Predicts Survival Outcomes. MERCURY Experience. J. Clin. Oncol. 2011; 28: 3753–3760. https://doi.org/10.1200/JCO.2011.34.9068.

98. Petrillo R., Balzarini L., Bidoli P. Ceglia E, D'Ippolito G, Tess JD, Musumeci R. Esophageal squamous cell carcinoma: MRI evaluation of mediastinum. Gastrointest. Radiol. 1990; 15: 275–278.

99. Patel U.B., Brown G., Rutten H., West N., Sebag-Montefiore D., Glynne-Jones R., Rullier E., Peeters M., Van Cutsem E., Ricci S., Van de Velde C., Kjell P., Quirke P. Comparison of Magnetic Resonance Imaging and Histo pathological Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. Ann. Surg. Oncol. 2012; 9: 2842–2852. https://doi.org/10.1245/s10434-012-2309-3.

100. Nishimura H., Tanigawa N., Hiramatsu M., Tatsumi Y., Matsuki M., Narabayashi I. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superpara magnetic iron oxide. J. Am. Coll. Surg. 2006; 202: 604–611.

101. Koh D.M., Padhani A.R. Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. Br. J. Radiol. 2006; 79: 633–635.

102. Mizowaki T., Nishimura Y., Shimada Y., Nakano Y., Imamura M., Konishi J., Hiraoka M. Optimal size criteria of malignant lymph nodes in the treatment planning of radiotherapy for esophageal cancer: evaluation by computed tomography and magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 1996; 36: 1091–1098.

103. Patel U.B., Brown G. MRI-based assessment of tumor regression in rectal cancer. Curr. Colorectal Cancer Rep. 2013; 2: 136–145.

104. Alper F., Turkyilmaz A., Kurtcan S. Aydin Y., Onbas O., Acemoglu H., Eroglu A. Effectiveness of the STIR turbo spin-echo sequence MR imaging in evaluation oflymphadenopathy in esophageal cancer. J. Radiol. 2011; 80: 625–628.

105. Cobelli F.D., Giganti F., Orsenigo E. Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology. Eur. Radiol. 2013; 23: 2165–2174. https://doi.org/10.1007/s00330-013-2807-0.

106. van Hagen P., Hulshof M.C.C.M., van Lanschot J.J., Steyerberg E.W., van Berge Henegouwen M.I., Wijnhoven B.P., Richel D.J., Nieuwenhuijzen G.A., Hospers G.A., Bonenkamp J.J., Cuesta M.A., Blaisse R.J., Busch O.R., ten Kate F.J., Creemers G.J., Punt C.J., Plukker J.T., Verheul H.M., Spillenaar Bilgen E.J., van Dekken H., van der Sangen M.J., Rozema T., Biermann K., Beukema J.C., Piet A.H., van Rij C.M., Reinders J.G., Tilanus H.W., van der Gaast A. CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 2012; 22: 2074–2084. https://doi.org/10.1056/NEJMoa1112088.

107. Heethuis S.E., Goense L., van Rossum P.S.N. DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer. Acta Oncol. 2018; 57: 1201–1208. https://doi.org/10.1080/0284186X.2018.1473637.

108. Dvoreckij S.Ju. Modern esophageal cancer treatment strategy. Vestnik khirurgii im. I.I. Grekova. 2016. 4: 102–107. https://doi.org/10.24884/0042-4625-2016-175-4-102-107. (In Russian)

109. Mandard A.M., Dalibard F., Mandard J.C., Marnay J., Henry-Amar M., Petiot J.H., Roussel A., Jacob J.H., Segol P., Samama G., Ollivier J.M., Bonvalot S., Gignoux M. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994. 11: 2680–2686.

110. Sendler A. Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res. 2010; 182: 167–177. https://doi.org/10.1007/978-3-540-70579-6_14

111. Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., Scarffe J.H., Lofts F.J., Falk S.J., Iveson T.J., Smith D.B., Langley R.E., Verma M., Weeden S., Chua Y.J., MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006; 355: 11–20.

112. Schandl A., Lagergren J., Johar A., Lagergren P. Healthrelated quality of life 10 years after oesophageal cancer surgery. Eur. J. Cancer. 2016; 69: 43–50. https://doi.org/10.1016/j.ejca.2016.09.032.

113. Hayashida Y., Yakushiji T., Awai K., Katahira K., Nakayama Y., Shimomura O., Kitajima M., Hirai T., Yamashita Y., Mizuta H. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur. Radiol. 2006; 16: 2637–2643.

114. Galban C.J., Mukherji S.K., Chenevert T.L., Meyer C.R., Hamstra D.A., Bland P.H., Johnson T.D., Moffat B.A., Rehemtulla A., Eisbruch A., Ross B.D. A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl. Oncol. 2009; 2: 184–190.

115. Sun N.N., Liu C., Ge X.L. Dynamic contrast-enhanced MRI for advanced esophageal cancer response assessment after concurrent chemoradiotherapy. Diagn. Interv. Radiol. 2018; 24: 195–202. https://doi.org/10.5152/dir.2018.17369.

116. Patterson D.M., Padhani A.R., Collins D.J. Technology insight: water diffusion MRI – a potential new biomarker of response to cancer therapy. Nat. Clin. Pract. Oncol. 2008; 4: 220–233. https://doi.org/10.1038/ncponc1073.

117. Aoyagi T., Shuto K., Okazumi S., Shimada H., Kazama T., Matsubara H. Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer. Dig. Surg. 2011; 4: 252–257. https://doi.org/10.1159/000328770.

118. van Rossum P.S., van Lier A.L., van Vulpen M., Reerink O., Lagendijk J.J., Lin S.H., van Hillegersberg R., Ruurda J.P., Meijer G.J., Lips I.M. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer. Radiother. Oncol. 2015; 2: 163–170. https://doi.org/10.1016/j.radonc.2015.04.027.

119. De Cobelli F., Giganti F., Orsenigo E., Cellina M., Esposito A., Agostini G., Albarello L., Mazza E., Ambrosi A., Socci C., Staudacher C., Del Maschio A. Apparent diffusion coefficient modifications in assessing gastrooesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology. Eur. Radiol. 2013; 8: 2165–2174. https://doi.org/10.1007/s00330-013-2807-0.

120. Wang L., Liu L., Han C., Liu S., Tian H., Li Z., Ren X., Shi G., Wang Q., Wang G. The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy. Radiother. Oncol. 2016; 2: 246–251. https://doi.org/10.1016/j.radonc.2016.10.021.

121. Patel U.B., Taylor F., Blomqvist L., George C., Evans H., Tekkis P., Quirke P., Sebag-Montefiore D., Moran B., Heald R., Guthrie A., Bees N., Swift I., Pennert K., Brown G. Magnetic Resonance Imaging-Detected Tumor Response for Locally Advanced Rectal Cancer Predicts Survival Outcomes. MERCURY Experience. J. Clin. Oncol. 2011; 28: 3753–3760. https://doi.org/10.1200/JCO.2011.34.9068.

122. Patel U.B., Brown G., Rutten H., West N., Sebag-Montefiore D., Glynne-Jones R., Rullier E., Peeters M., Van Cutsem E., Ricci S., Van de Velde C., Kjell P., Quirke P. Comparison of Magnetic Resonance Imaging and Histo pathological Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. Ann. Surg. Oncol. 2012; 9: 2842–2852. https://doi.org/10.1245/s10434-012-2309-3.

123. Koh D.M., Padhani A.R. Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. Br. J. Radiol. 2006; 79: 633–635.

124. Patel U.B., Brown G. MRI-based assessment of tumor regression in rectal cancer. Curr. Colorectal Cancer Rep. 2013; 2: 136–145.

125. Cobelli F.D., Giganti F., Orsenigo E. Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology. Eur. Radiol. 2013; 23: 2165–2174. https://doi.org/10.1007/s00330-013-2807-0.

126. Heethuis S.E., Goense L., van Rossum P.S.N. DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer. Acta Oncol. 2018; 57: 1201–1208. https://doi.org/10.1080/0284186X.2018.1473637.